Venous thromboembolism in multiple myeloma–choice of prophylaxis, role of direct oral anticoagulants and special considerations D Swan, A Rocci, C Bradbury, J Thachil British Journal of Haematology 183 (4), 538-556, 2018 | 59 | 2018 |
Thrombosis in immune thrombocytopenia—current status and future perspectives D Swan, A Newland, F Rodeghiero, J Thachil British journal of haematology 194 (5), 822-834, 2021 | 41 | 2021 |
Beyond DNA damage: exploring the immunomodulatory effects of cyclophosphamide in multiple myeloma D Swan, M Gurney, J Krawczyk, AE Ryan, M O’Dwyer Hemasphere 4 (2), e350, 2020 | 35 | 2020 |
The problem of under-diagnosis and over-diagnosis of pulmonary embolism D Swan, S Hitchen, FA Klok, J Thachil Thrombosis research 177, 122-129, 2019 | 22 | 2019 |
Management of bleeding and procedures in patients on antiplatelet therapy D Swan, N Loughran, M Makris, J Thachil Blood Reviews 39, 100619, 2020 | 19 | 2020 |
Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma D Swan, K Lynch, M Gurney, M O’Dwyer Therapeutic advances in hematology 10, 2040620719854171, 2019 | 19 | 2019 |
The evolving status of immunotherapies in multiple myeloma: The future role of bispecific antibodies D Swan, D Routledge, S Harrison British Journal of Haematology 196 (3), 488-506, 2022 | 16 | 2022 |
The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal … S Sarkar, SKS Chauhan, J Daly, A Natoni, H Fairfield, R Henderson, ... Cancer Immunology, Immunotherapy 69, 421-434, 2020 | 16 | 2020 |
Bispecific antibodies in multiple myeloma: opportunities to enhance efficacy and improve safety D Swan, P Murphy, S Glavey, J Quinn Cancers 15 (6), 1819, 2023 | 15 | 2023 |
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular … SD Naicker, CL Feerick, K Lynch, D Swan, C McEllistrim, R Henderson, ... Oncoimmunology 10 (1), 1859263, 2021 | 14 | 2021 |
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation … D Swan, PJ Hayden, DJ Eikema, L Koster, S Sauer, D Blaise, E Nicholson, ... British Journal of Haematology 197 (1), 82-96, 2022 | 11 | 2022 |
Heparin–Messias or Verschlimmbesserung? D Swan, M Carrier, T Lisman, J Thachil Journal of Thrombosis and Haemostasis 19 (10), 2373-2382, 2021 | 10 | 2021 |
Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t (11; 14) D Swan, C Delaney, A Natoni, M O’Dwyer, J Krawczyk haematologica 105 (3), e141, 2020 | 10 | 2020 |
Port removal in patients receiving emicizumab prophylaxis: A single centre experience and review of the literature D Swan, S Paran, B Nolan Haemophilia 28 (1), 42-45, 2022 | 8 | 2022 |
Non‐factor therapies for bleeding disorders: A primer for the general haematologist D Swan, J Mahlangu, J Thachil EJHaem 3 (3), 584-595, 2022 | 7 | 2022 |
Vaccine-induced thrombosis and thrombocytopenia (VITT) in Ireland: a review of cases and current practices D Swan, H Enright, R Desmond, G Le, E El Hassadi, B Hennessy, F Lynott, ... Thrombosis Update 5, 100086, 2021 | 7 | 2021 |
A review of anticoagulation in patients with central nervous system malignancy: between a rock and a hard place D Swan, DJ Seiffge, J Thachil Journal of neurology 268 (7), 2390-2401, 2021 | 5 | 2021 |
Reintroduction of anticoagulant therapy after intracranial haemorrhage: If and when? M Scott, R Low, D Swan, J Thachil Blood Reviews 32 (3), 256-263, 2018 | 5 | 2018 |
Practical management of the haemorrhagic complications of myeloproliferative neoplasms E Jones, B Dillon, D Swan, J Thachil British Journal of Haematology 199 (3), 313-321, 2022 | 4 | 2022 |
Thromboprophylaxis in COVID-19–Rationale and considerations S Bristogiannis, D Swan, J Thachil Advances in Biological Regulation 81, 100819, 2021 | 4 | 2021 |